Literature DB >> 21057205

Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.

Frank Desarnaud1, Peter Geck, Christopher Parkin, Gino Carpinito, Andrew N Makarovskiy.   

Abstract

The molecular mechanisms conferring resistance to docetaxel in prostate cancer patients remain partially understood. We generated docetaxel resistant derivatives of the androgen independent prostate cancer cell lines PC-3 and DU-145. Docetaxel rapidly induces DU-145 cell death via apoptosis and the drug resistant cells were produced by periodically exposing proliferating DU-145 cultures to small doses of docetaxel. In PC-3 cells docetaxel induces delayed cell death via mitotic catastrophe evident by profound multinucleation and formation of giant cells. Mononucleated progeny of the giant PC-3 cells shows significant resistance to docetaxel. Gene expression profiling of these docetaxel resistant PC-3 cells revealed sets of docetaxel inducible and constitutively expressed genes associated with major cancer pathways. A contradictory overlap with DU-145 docetaxel resistant cells was also found. Analyses suggested significant changes associated with apoptotic function, DNA repair, cell growth, survival and proliferation, metabolism, maintenance of cytoskeleton and extracellular matrix formation. These cellular processes often contribute to drug resistance and our study identified a set of genes managing this phenotype. Additional analyses of the drug resistant PC-3 cells using shRNA constructs determined direct relevance of Cyclin G2 to docetaxel resistance as well as prevention of multinucleation, whereas the knockdown of upregulated CYP1B1 showed no effect on either of these processes. Downregulated GBP1 was explored by ectopic overexpression and even though GBP1 has a potential to mediate resistance to docetaxel, it was not utilized in PC-3 cells. The results suggest complex combination of gene expression pattern changes that enables resistance to docetaxel while preventing death via multinucleation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21057205      PMCID: PMC3230309          DOI: 10.4161/cbt.11.2.13750

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  36 in total

1.  Cyclin G2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a p53-dependent cell cycle arrest.

Authors:  Aruni S Arachchige Don; Robert F Dallapiazza; David A Bennin; Tiffany Brake; Colleen E Cowan; Mary C Horne
Journal:  Exp Cell Res       Date:  2006-09-29       Impact factor: 3.905

2.  RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis.

Authors:  Fangxin Hong; Rainer Breitling; Connor W McEntee; Ben S Wittner; Jennifer L Nemhauser; Joanne Chory
Journal:  Bioinformatics       Date:  2006-09-18       Impact factor: 6.937

3.  Genomic signatures to guide the use of chemotherapeutics.

Authors:  Anil Potti; Holly K Dressman; Andrea Bild; Richard F Riedel; Gina Chan; Robyn Sayer; Janiel Cragun; Hope Cottrill; Michael J Kelley; Rebecca Petersen; David Harpole; Jeffrey Marks; Andrew Berchuck; Geoffrey S Ginsburg; Phillip Febbo; Johnathan Lancaster; Joseph R Nevins
Journal:  Nat Med       Date:  2006-10-22       Impact factor: 53.440

4.  KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer.

Authors:  M Bloch; J Ousingsawat; R Simon; P Schraml; T C Gasser; M J Mihatsch; K Kunzelmann; L Bubendorf
Journal:  Oncogene       Date:  2006-12-04       Impact factor: 9.867

5.  Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter.

Authors:  Fabio Stossi; Varsha S Likhite; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  J Biol Chem       Date:  2006-04-10       Impact factor: 5.157

6.  Dominant negative suppression of Rad leads to QT prolongation and causes ventricular arrhythmias via modulation of L-type Ca2+ channels in the heart.

Authors:  Hirotaka Yada; Mitsushige Murata; Kouji Shimoda; Shinsuke Yuasa; Haruko Kawaguchi; Masaki Ieda; Takeshi Adachi; Mitsuru Murata; Satoshi Ogawa; Keiichi Fukuda
Journal:  Circ Res       Date:  2007-05-24       Impact factor: 17.367

7.  Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.

Authors:  Tristan M Sissung; Romano Danesi; Douglas K Price; Seth M Steinberg; Ronald de Wit; Muhammad Zahid; Nilesh Gaikwad; Ercole Cavalieri; William L Dahut; Dan L Sackett; William D Figg; Alex Sparreboom
Journal:  Mol Cancer Ther       Date:  2008-01-09       Impact factor: 6.261

8.  CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance.

Authors:  V G Martinez; R O'Connor; Y Liang; M Clynes
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

9.  The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.

Authors:  Ahmed Ashour Ahmed; Anthony D Mills; Ashraf E K Ibrahim; Jillian Temple; Cherie Blenkiron; Maria Vias; Charlie E Massie; N Gopalakrishna Iyer; Adam McGeoch; Robin Crawford; Barbara Nicke; Julian Downward; Charles Swanton; Stephen D Bell; Helena M Earl; Ronald A Laskey; Carlos Caldas; James D Brenton
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

10.  Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer.

Authors:  Q Wang; M Williamson; S Bott; N Brookman-Amissah; A Freeman; J Nariculam; M J F Hubank; A Ahmed; J R Masters
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

View more
  9 in total

Review 1.  Pathophysiological role of guanylate-binding proteins in gastrointestinal diseases.

Authors:  Nathalie Britzen-Laurent; Christian Herrmann; Elisabeth Naschberger; Roland S Croner; Michael Stürzl
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 2.  Genetic variation: effect on prostate cancer.

Authors:  Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi
Journal:  Biochim Biophys Acta       Date:  2014-09-06

Review 3.  Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

4.  T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression.

Authors:  Dana A M Mustafa; Rute M S M Pedrosa; Marcel Smid; Marcel van der Weiden; Vanja de Weerd; Alex L Nigg; Cor Berrevoets; Lona Zeneyedpour; Neibla Priego; Manuel Valiente; Theo M Luider; Reno Debets; John W M Martens; John A Foekens; Anieta M Sieuwerts; Johan M Kros
Journal:  Acta Neuropathol       Date:  2018-01-19       Impact factor: 17.088

5.  Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells.

Authors:  Verónica Cánovas; Yolanda Puñal; Valentina Maggio; Enric Redondo; Mercedes Marín; Begoña Mellado; Mireia Olivan; Matilde Lleonart; Jacques Planas; Juan Morote; Rosanna Paciucci
Journal:  Oncotarget       Date:  2017-07-22

6.  Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance.

Authors:  Motoi Fukumoto; Tatsuya Amanuma; Yoshikazu Kuwahara; Tsutomu Shimura; Masatoshi Suzuki; Shiro Mori; Hiroyuki Kumamoto; Yohei Saito; Yasuhito Ohkubo; Zhenfeng Duan; Kenji Sano; Tomohiro Oguchi; Kazuyuki Kainuma; Shinichi Usami; Kengo Kinoshita; Inchul Lee; Manabu Fukumoto
Journal:  Cancer Sci       Date:  2014-09-29       Impact factor: 6.716

7.  Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.

Authors:  Nader Al Nakouzi; Sophie Cotteret; Frédéric Commo; Catherine Gaudin; Shanna Rajpar; Philippe Dessen; Philippe Vielh; Karim Fizazi; Anne Chauchereau
Journal:  Oncotarget       Date:  2014-02-15

8.  Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Alessandro Colapietro; Francesco Marampon; Roberta Sferra; Simona Pompili; Leda Assunta Biordi; Roberto Iorio; Vincenzo Flati; Christian Argueta; Yosef Landesman; Michael Kauffman; Sharon Shacham; Claudio Festuccia
Journal:  Oncotarget       Date:  2017-11-30

9.  Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.

Authors:  Yoshinori Matsuda; Shintaro Narita; Taketoshi Nara; Huang Mingguo; Hiromi Sato; Atsushi Koizumi; Sohei Kanda; Kazuyuki Numakura; Mitsuru Saito; Takamitsu Inoue; Yuko Hiroshima; Hiroshi Nanjo; Shigeru Satoh; Norihiko Tsuchiya; Tomonori Habuchi
Journal:  BMC Cancer       Date:  2020-04-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.